Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Strickland

Nurse Practitioner, Family Gainesville, FL Nurse Practitioner

NPI 1639360589 CMS profile 10907333

4423 Nw 6Th Pl Ste A, Gainesville, FL 32607

Open in the dashboard

General payments

$10,411

153 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Strickland of Gainesville, FL is reported in the CMS Open Payments database as having received $10,411 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $865 35
2024 General $1,538 33
2023 General $6,308 38
2022 General $856 21
2021 General $844 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Strickland
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Katherine Strickland were reported at $865. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Katherine Strickland Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $844 $124 $35–$379 $132
2022 $856 $141 $44–$430 $149
2023 $6,308 $154 $49–$476 $160
2024 $1,538 $165 $51–$504 $164
2025 $865 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Fresenius USA Marketing, Inc. $6,698 65 payments
  2. Relypsa, Inc. $879 41 payments
  3. AstraZeneca Pharmaceuticals LP $466 9 payments
  4. Genzyme Corporation $320 4 payments
  5. Amgen Inc. $299 4 payments
  6. Ardelyx, Inc. $236 2 payments
  7. Retrophin, Inc. $233 2 payments
  8. Akebia Therapeutics Inc $231 11 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $187 2 payments
  10. Pharming Healthcare, Inc. $130 1 payment
  11. Other $733 12 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,783 144 payments
  2. Honoraria $4,500 3 payments
  3. Travel and Lodging $933 3 payments
  4. Education $195 3 payments
Products named General payments · program years 2021–2025
  1. Velphoro $6,698 65 payments
  2. Veltassa Hyperkalemia $473 31 payments
  3. Parsabiv $299 4 payments
  4. LOKELMA $290 7 payments
  5. XPHOZAH 30 MG $236 2 payments
  6. Auryxia $206 10 payments
  7. Kerendia $187 2 payments
  8. Veltassa Nephrology $176 7 payments
  9. RUCONEST $130 1 payment
  10. WATCHMAN FLX $125 1 payment
  11. Other $1,128 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,392

Median for Nurse Practitioner: 389

Drug cost

$1,332,719

Median for Nurse Practitioner: $21,885

Branded share of claims

44.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Velphoro Sucroferric Oxyhydroxide Brand 226 $561,614
Auryxia Ferric Citrate Brand 234 $511,120
Veltassa Patiromer Calcium Sorbitex Brand 73 $97,874
Sevelamer Carbonate Generic 295 $65,596
Lokelma Sodium Zirconium Cyclosilicate Brand 25 $37,206
Renvela Sevelamer Carbonate Brand 14 $27,679
Lanthanum Carbonate Generic 35 $21,202
Clonidine Generic 17 $3,335
Midodrine Hcl Generic 14 $2,011
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 40 $700

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$12,276

Medicare's payments for the services billed

Medicare patients

49

Average age 68

Services billed

186

28 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 73%
Heart failure 71%
Arthritis 63%
Ischemic heart disease 61%
Depression 51%
Atrial fibrillation 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Velphoro
  • Fresenius USA Marketing, Inc. $676
$676 226 —
Veltassa
  • Relypsa, Inc. $197
$197 73 —
RUCONEST
  • Pharming Healthcare, Inc. $130
$130 — —
XPHOZAH 30 MG
  • Ardelyx, Inc. $118
$118 — —
Parsabiv
  • Amgen Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record